Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

N30: Understanding Inflammatory Bowel Disease Emergency Department Admissions in a Tertiary Referral Inflammatory Bowel Disease Centre in England: A quality Improvement projectECCO’23 Copenhagen
Year: 2023
Authors: Avery, P.(1)*;Younge, L.(1);Arebi, N.(1);
(1)St Marks Specialist Bowel Hospital and Academic Institute, Inflammatory Bowel Disease, London, United Kingdom;
N31: Nothing about us, without us: Developing a reliable IBD information source on sexual well-being by patients and for patientsECCO’23 Copenhagen
Year: 2023
Authors: Fourie, S.(1);Johnstone, L.(1)*;Czuber-Dochan, W.(2);
(1)University of Oxford, Radcliffe Department of Medicine, Oxford, United Kingdom;(2)King's College of London, Florence Nightingale Faculty of Nursing- Midwifery and palliative Care, London, United Kingdom;
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn's diseaseECCO’23 Copenhagen
Year: 2023
Authors: Verstockt, S.(1)*;Machiels, K.(1);Dehairs, J.(2);Rems, K.(1);De Greef, I.(1);Jans, D.(3);Sabino, J.(1,4);Ferrante, M.(1,4);Vermeire, S.(1,4);Verstockt, B.(1,4);
(1)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing CHROMETA, Leuven, Belgium;(2)KU Leuven, Department of Oncology, Leuven, Belgium;(3)KU Leuven, Department of Human Genetics, Leuven, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn's disease patients stopping infliximabECCO’23 Copenhagen
Year: 2023
Authors: PierreDr., N.(1)*;Huynh-Thu, V.A.(2);Baiwir, D.(3);Mazzucchelli, G.(4);Fléron, M.(3);Trzpiot, L.(4);Eppe, G.(4);Laharie, D.(5);Satsangi, J.(6);Colombel, J.F.(7);Hertervig, E.(8);Meuwis, M.A.(1);Louis, E.(9);
(1)University of Liege, Laboratory of Translational Gastroenterology, Liege, Belgium;(2)University of Liege, Department of Electrical Engineering and Computer Science, Liege, Belgium;(3)University of Liege, GIGA Proteomics Facility, Liege, Belgium;(4)University of Liege, Laboratory of Mass Spectrometry, Liege, Belgium;(5)Centre Hospitalier Universitaire de Bordeaux, Service d'Hépato-gastroentérologie et oncologie digestive, Bordeaux, France;(6)John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom;(7)Icahn School of Medicine at Mount Sina, Division of Gastroenterology, New York, United States;(8)Skane University Hospital, Department of Gastroenterology, Lund, Sweden;(9)Liege University Hospital, Hepato-Gastroenterology and Digestive Oncology Department, Liege, Belgium;GETAID and the SPARE-Biocycle research group
OP03: Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn's disease patients: The EPIC-CD studyECCO’23 Copenhagen
Year: 2023
Authors: JoustraMD., V.(1)*;Li Yim, A.(2,3);Hageman, I.(2);Levin, E.(4);Noble, A.(5);Chapman, T.(6);McGregor, C.(6);Adams, A.(6);Satsangi, J.(6);de Jonge, W.(2);Henneman, P.(3);D'Haens, G.(1);
(1)Amsterdam UMC location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC location AMC, Tytgat institute for Liver and Intestinal Research, Amsterdam, The Netherlands;(3)Amsterdam UMC location AMC, Genome Diagnostics Laboratory- Department of Clinical Genetics, Amsterdam, The Netherlands;(4)Horaizon, bv, Delft, The Netherlands;(5)Oxford University - Hospitals NHS Foundation Trust - John Radcliffe Hospital, Translational Gastroenterology Unit - NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom;(6)Oxford University- Hospitals NHS Foundation Trust- John Radcliffe Hospital, Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom;on behalf of the EPIC-CD Consortium
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patientsECCO’23 Copenhagen
Year: 2023
Authors: Vermeire, S.(1)*;Danese, S.(2);Hébuterne, X.(3);D'Haens, G.(4);Takeuchi, K.(5);Finney-Hayward, T.(6);Klaff, J.(6);Holweg, C.T.J.(6);Rubin, D.T.(7);
(1)University Hospital Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(2)Humanitas Clinical and Research Center - IRCCS - and Humanitas University, Department of Biomedical Sciences, Milan, Italy;(3)University Côte d'Azur, Gastroentérology and Clinical Nutrition, Nice, France;(4)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Tsujinaka Hospital Kashiwanoha, IBD Center- Department of Gastroenterology and Hepatology, Chiba, Japan;(6)AbbVie Inc, Immunology, North Chicago, United States;(7)University of Chicago Medicine, Section of Gastroenterology- Hepatology and Nutrition, Chicago, United States;
OP05: High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisECCO’23 Copenhagen
Year: 2023
Authors: Pibiri, P.(1)*;Sun, S.(1);Karmi, N.(1);Oelen, R.(2);de Jong, S.(1);Bangma, A.(1);Hermoso, M.(1);Paraskevopoulou, M.(3);Farahmand, S.(3);Weersma, R.(1);Bigaeva, E.(1);Festen, E.(1);Xia, G.(3);Teunis, J.(4);Bleck, B.(3);
(1)University Medical Center Groningen, Hepatology and Gastroenterology, Groningen, The Netherlands;(2)University Medical Center Groningen, Genetics, Groningen, The Netherlands;(3)Takeda Pharmaceuticals, GI Drug Discovery Unit, Cambridge MA, United States;(4)University Medical Center Groningen, Flow Cytometry Unit, Groningen, The Netherlands;
OP06: Multiomic interrogation of the epithelium in active Ulcerative Colitis reveals dysregulated myeloid cells associated with non-response to anti-Tumour Necrosis Factor therapy.ECCO’23 Copenhagen
Year: 2023
Authors: Jha , D.(1)*;Al-Taie , Z.(2);Krek , A.(3);Eshghi , S.(4);Tankelevich , M.(1);Meringer , H.(5);Cossarini , F.(6);Canales-Herrerias , P.(1);Livanos , A.E.(1); Polydorides , A.D.(7);Martin , J.(8);Ko , H.M.(9);McBride , J.(4);Hackney , J.(10);Colombel , J.F.(1);Argmann , C.(11);Suarez-Farinas , M.(11);Petralia , F.(11);Mehandru , S.(1);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States;(2)Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences- Population Health Science and Policy, New York City, United States;(3)Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences-, New York City, United States;(4)Genentech Inc, OMNI Biomarker Development, San Francisco, United States;(5)Assuta Ashdod Medical Center, Department of Gastroenterology and Liver diseases, Ashdod, Israel;(6)Icahn School of Medicine at Mount Sinai, Infectious Diseases, New York City, United States;(7)Icahn School of Medicine at Mount Sinai, Pathology, New York City, United States;(8)Université de Nantes, Centre de Recherche en Transplantation et Immunologie, Nantes, France;(9)Columbia University, Pathology, New York City, United States;(10)Genentech Inc, OMNI Bioinformatics, San Francisco, United States;(11)Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York City, United States;
OP07: Absolute and relative risks of kidney and urological complications in patients with Inflammatory Bowel DiseaseECCO’23 Copenhagen
Year: 2023
Authors: Yang, Y.(1)*;Ludviggson, J.F.(1,2);Olén, O.(3,4,5);Sjölander, A.(1);Carrero, J.J.(1,6);
(1)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(2)Örebro University Hospital, Department of Paediatrics, Örebro, Sweden;(3)Karolinska Institutet, Clinical Epidemiology Division- Department of Medicine Solna, Stockholm, Sweden;(4)Stockholm South General Hospital, Sachs' Children and Youth Hospital, Stockholm, Sweden;(5)Karolinska Institutet, Department of Clinical Science and Education- Södersjukhuset, Stockholm, Sweden;(6)Karolinska Institutet, Division of Nephrology- Department of Clinical Sciences- Danderyd Hospital, Stockholm, Sweden;
OP08: Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trialECCO’23 Copenhagen
Year: 2023
Authors: Jairath, V.(1,2)*;Feagan, B.G.(2);Silverberg, M.S.(3);Danese, S.(4);Gionchetti, P.(5);Löwenberg, M.(6);Bressler, B.(7);Ferrante, M.(8);Hart, A.(9);Lindner, D.(10);Escher, A.(10);Jones, S.(10);Shen, B.(11);Travis, S.(12);
(1)Department of Medicine- Division of Gastroenterology, Western University, London- ON, Canada;(2)Alimentiv, Alimentiv, London- ON, Canada;(3)Mount Sinai Hospital, Division of Gastroenterology- Department of Medicine- Mount Sinai Hospital Inflammatory Bowel Disease Centre, Toronto- ON, Canada;(4)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)University of Bologna, IRCCS Azienda Ospedaliera-Universitaria di Bologna, Bologna, Italy;(6)Amsterdam University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)University of British Columbia, Department of Medicine- Division of Gastroenterology, Vancouver- BC, Canada;(8)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(9)St Mark's Hospital and Imperial College London, IBD Unit, London, United Kingdom;(10)Takeda, Takeda, Zurich, Switzerland;(11)Columbia University Irving Medical Center, Gastroenterology, New York- NY, United States;(12)John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom;
OP09: Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras – Results from a Western Hungarian Population-based Inception Cohort between 1977–2020ECCO’23 Copenhagen
Year: 2023
Authors: LakatosPhD, P.L.(1)*;Gonczi, L.(2);Lakatos, L.(3);Golovics, P.A.(4);Pandur, T.(5);David, G.(3);Erdelyi, Z.(3);Szita , I.(3);
(1)Mcgill University Health Center, IBD Centre, Montréal, Canada;(2)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(3)Ferenc Csolnoky Hospital, Department of Gastroenterology, Veszprem, Hungary;(4)Hungarian Defence Forces Medical Centre, Department of Gastroenterology, Budapest, Hungary;(5)Grof Esterhazy Hospital, Department of Gastroenterology, Papa, Hungary;
OP10: Proctocolectomy with permanent ileostomy is associated with better transplant-free survival in patients with primary sclerosing cholangitis: a retrospective cohort studyECCO’23 Copenhagen
Year: 2023
Authors: Mol, B.(1)*;van Nieuwamerongen, M.(1);van Munster, K.(1);van Munster, S.(1);de Vries, A.(2);van der Meer, A.(2);Goet, J.(2);Weersma, R.(3);Inderson, A.(4);Boonstra, K.(1);van Meer, S.(5);de Boer, Y.(1);Spanier, M.(6);Drenth, J.(7);de Vries, E.(8);Beuers, U.(1);Bogaards, J.(9);Ponsioen, C.(1);
(1)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands;(3)University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(4)Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, The Netherlands;(5)University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, The Netherlands;(6)Rijnstate Hospital, Gastroenterology and Hepatology, Arnhem, The Netherlands;(7)Radboud University Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(8)Isala Hospital, Gastroenterology and Hepatology, Zwolle, The Netherlands;(9)Amsterdam UMC, Epidemiology and Data Science, Amsterdam, The Netherlands;EpiPSC2
OP11: Ileocecal resection for recently diagnosed ileocecal Crohn's disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based study.ECCO’23 Copenhagen
Year: 2023
Authors: Agrawal, M.(1,2)*;Ebert, A.(2);Poulsen, G.(2);Ungaro, R.(1);Faye, A.(3);Jess, T.(2,4);Colombel, J.F.(1);Allin, K.(2,4);
(1)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Aalborg University, Center for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;(3)NYU Grossman School of Medicine, Division of Gastroenterology, New York, United States;(4)Aalborg University Hospital, Department of Gastroenterology & Hepatology, Aalborg, Denmark;
OP12: does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRNECCO’23 Copenhagen
Year: 2023
Authors: Focht, G.(1)*;Lujan, R.(1);Atia, O.(1);Greenfeld, S.(2);Kariv, R.(2);Loewenberg Weisband, Y.(3);Lederman, N.(4);Matz, E.(5);Dotan, I.(6);Turner, D.(1);
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Israel and the Sackler Faculty of Medicine, Maccabi Health Services, Tel Aviv, Israel;(3)Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel;(4)Medical Division, Meuhedet Sick Fund, Tel Aviv, Israel;(5)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(6)Rabin Medical Center and the Sackler Faculty of Medicine, Division of Gastroenterology, Petah Tikva, Israel;
OP13: Postoperative Crohn's disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop.ECCO’23 Copenhagen
Year: 2023
Authors: Riviere, P.(1)*;Dragoni, G.(2);Allez, M.(3);Allocca, M.(4);Arebi, N.(5);Bemelman, W.(6);Bislenghi, G.(7);Brown, S.(8);Carvello, M.(9);De Vries, A.(10);Domenech, E.(11);Hammoudi, N.(3);Kapizioni, C.(12);Kotze, P.G.(13);Mañosa, M.(11);Myrelid, P.(14);Oliveira-Cunha, M.(15);Noor, N.N.(16);Pellino, G.(17);Pouillon, L.(18);Savarino, E.(19);Verstockt, B.(20);Panis, Y.(21);Ferrante, M.(20);
(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)Careggi University Hospital, IBD Referral Center, Florence, Italy;(3)Hôpital Saint-Louis, Gastroenterology, Paris, France;(4)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)St Mark's Hospital, Inflammatory Bowel Disease, London, United Kingdom;(6)Amsterdam University Medical Centers, Surgery, Amsterdam, The Netherlands;(7)University Hospitals Leuven, Abdominal surgery, Leuven, Belgium;(8)Sheffield Teaching Hospitals, Surgery, Sheffield, United Kingdom;(9)Humanitas University, Biomedical Sciences, Milan, Italy;(10)Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands;(11)Hospital Universitari Germans Trias i Pujol, Gastroenterology and Hepatology, Badalona, Spain;(12)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(13)Pontificia Universidade Catolica do Parana, IBD Outpatient Clinics, Curitiba, Brazil;(14)Linkoping University Hospital, Surgery, Linkoping, Sweden;(15)University Hospitals of Birmingham, Colorectal Surgery, Birmingham, United Kingdom;(16)Addenbroke's Hospital, Gastroenterology, Cambridge, United Kingdom;(17)Universita Degli Studi Della Campania Luigi Vanvitelli, Advanced medical and surgical science, Napoli, Italy;(18)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(19)University of Padua, Surgery- Oncology and Gastroenterology, Padua, Italy;(20)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(21)Groupe Hospitalier Privé Ambroise Paré-Hartmann, Paris IBD Center, Neuilly sur Seine, France;The 8th ECCO Scientific Workshop
OP14: Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIOECCO’23 Copenhagen
Year: 2023
Authors: D'Haens, G.(1)*;Taxonera, C.(2);Lopez-Sanroman, A.(3);Nos Mateu, P.(4);Danese, S.(5);Armuzzi, A.(6);Roblin, X.(7);Peyrin-Biroulet, L.(8);West, R.(9);Witteman, B.(10);Duijvestein, M.(11);Gecse, K.(1);Hulshoff, M.(1);Mostafavi, N.(1);Clasquin, E.(1);Bouhnik, Y.(12);Laharie, D.(13);
(1)Amsterdam University Medical Centres, Gastroenterology, Amsterdam, The Netherlands;(2)Hospital Clinico San Carlos, Gastroenterology, Madrid, Spain;(3)Hospital Ramon Y Cajal, Gastroenterology, Madrid, Spain;(4)Hospital Universitario y Politecnico La Fe de Valencia, Gastroenterology, Valencia, Spain;(5)Instituto Clinico Humanitas, Gastroenterology, Rozzano, Italy;(6)IRCCS Humanitas Research Hospital, IBD Center, Rozzano- Milan, Italy;(7)CHU Saint-Etienne, Gastroenterology, Saint Priest, France;(8)CHRU de Nancy, Gastroenterology, Brabois, France;(9)Franciscus Gasthuis & Vlietland, Gastroenterology, Rotterdam, The Netherlands;(10)Ziekenhuis Gelderse Vallei, Gastroenterology, Ede, The Netherlands;(11)RadboudUMC, Gastroenterology, Nijmegen, The Netherlands;(12)Hopital Beaujon, Gastroenterology, Clichy, France;(13)Hopital du Haut-Leveque, Gastroenterology, Pessac, France;
OP15: Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extensionECCO’23 Copenhagen
Year: 2023
Authors: Danese, S.(1)*;Afif, W.(2);Abreu, M.(3);Sandborn, W.(4);Miao, Y.(5);Zhang, H.(5);Panaccione, R.(6);Hisamatsu, T.(7);Scherl, E.(8);Leong, R.(9);Rowbotham, D.(10);Arasaradnam, R.(11);Peyrin-Biroulet, L.(12);Sands, B.(13);Marano, C.(5);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(2)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(3)University of Miami, Miller School of Medicine, Miami, United States;(4)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(5)Janssen, Research & Development, Spring House, United States;(6)University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada;(7)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(8)New York Presbyterian Hospital, Weill Cornell Medicine, New York, United States;(9)Concord Hospital and Macquarie University Hospital, Gastroenterology, Sydney, Australia;(10)Auckland City Hospital, Gastroenterology, Auckland, New Zealand;(11)University of Warwick & University Hospital Coventry, Warwick Medical School, Coventry, United Kingdom;(12)Nancy University Hospital, Gastroenterology Department and Inserm U954, Vandœuvre-lès-Nancy, France;(13)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;UNIFI Investigators
OP16: Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn's disease by number and type of prior biologicsECCO’23 Copenhagen
Year: 2023
Authors: Peyrin-Biroulet, L.(1)*;Parkes, G.(2);Rodríguez, C.(3);Siffledeen, J.(4);Wright, J.(5);Broide, E.(6);Ford, S.(7);Lacerda, A.P.(7);Oomen, J.(7);Garrison, A.(7);Berg, S.(7);Rubin, D.T.(8);
(1)Lorraine University, Department of Gastroenterology- University Hospital of Nancy, Vandoeuvre, France;(2)Royal London Hospital, Department of Gastroenterology, London, United Kingdom;(3)University Hospital of Navarra, Department of Gastroenterology, Pamplona, Spain;(4)Covenant Health Grey Nuns Community Hospital, Division of Gastroenterology, Edmonton, Canada;(5)Kingsbury Hospital, Gastroenterology, Cape Town, South Africa;(6)Assaf Harofeh Medical Center, The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Zerifin, Israel;(7)AbbVie Inc., Research and Development, North Chicago, United States;(8)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
OP17: Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional TherapiesECCO’23 Copenhagen
Year: 2023
Authors: Feagan, B.G.(1)*;Horst, S.(2);Dryden, G.(3);Lindsay, J.O.(4);Ferrante, M.(5);Dubenco, E.(6);Lacerda, A.P.(6);Ford, S.(6);Anyanwu, S.I.(6);Zhou, Q.(6);Liu, J.(6);Chen, M.(7);Schreiber, S.(8);
(1)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;(2)Vanderbilt University Medical Center, Department of Gastroenterology- Hepatology- and Nutrition, Nashville, United States;(3)University of Louisville, Department of Microbiology & Immunology- Brown Cancer Center, Louisville, United States;(4)Queen Mary University of London, Centre for Immunobiology- Barts and the London School of Medicine and Dentistry-, London, United Kingdom;(5)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(6)AbbVie, none, North Chicago, United States;(7)The First Affiliated Hospital of Sun Yat-sen University, Division of Gastroenterology, Guangzhou, China;(8)Christian-Alrechts-University, Department Internal Medicine, Kiel, Germany;
OP18: Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohortECCO’23 Copenhagen
Year: 2023
Authors: Wewer, M.D.(1)*;Salupere, R.(2);Kievit, H.A.L.(3);Nielsen, K.R.(4);Midjord, J.(4);Domislovic, V.(5);Krznarić, Ž.(5);Pedersen, N.(6);Kjeldsen, J.(7);Eriksson, C.(8);Halfvarson, J.(8);Talbot, A.(9);Sebastian, S.(9);Goldis, A.(10);Misra, R.(11);Arebi, N.(11);Ilus, T.(12);Oksanen, P.(12,13);Neuman, A.(14);Andersen, V.(15,16,17);Skamnelos, A.(18);Katsanos, K.H.(18);Platon, V.(19);Turcan, S.(19);Borg, B.(20);Ellul, P.(20);Kupcinskas, J.(21);Kiudelis, G.(21);Yzet, C.(22);Fumery, M.(22);Kaimakliotis, I.P.(23);Lorenzon, G.(24);D'Inca, R.(24);Hernandez, V.(25,26);Fernandez, A.(27);Langholz, E.(28);Munkholm, P.(29);Burisch, J.(1);
(1)University Hospital Copenhagen – Amager and Hvidovre Hospital, Gastrounit- Medical Division, Hvidovre, Denmark;(2)Tartu University Hospital- University of Tartu, Division of Gastroenterology, Tartu, Estonia;(3)Herning central Hospital, Department of Medicine, Herning, Denmark;(4)National Hospital of the Faroe Islands, Medical Department, Thorshavn, Faroe Islands;(5)University Hospital Centre Zagreb, Department of Gastroenterology- Hepatology and Nutrition, Zagreb, Croatia;(6)Slagelse Regional Hospital, Gastroenterology Department, Slagelse, Denmark;(7)Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark;(8)Faculty of Medicine and Health- Örebro University, Department of Gastroenterology, Örebro, Sweden;(9)Hull University Teaching Hospitals NHS Trust- Hull, Department of Gastroenterology, Hull, United Kingdom;(10)University of Medicine ‘Victor Babes', Clinic of Gastroenterology, Timisoara, Romania;(11)Imperial College London, IBD Department, London, United Kingdom;(12)Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland;(13)Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland;(14)Viborg hospital, Medical Department, Viborg, Denmark;(15)University Hospital of Southern Denmark, Institute of Regional Health Research- Research unit of Molecular Diagnostics and Clinical Research, Aabenraa & Sønderborg, Denmark;(16)University of Southern Denmark, Institute of Molecular Medicine, Odense, Denmark;(17)University of Southern Denmark, Institute of Regional Research, Odense, Denmark;(18)University Hospital and University of Ioannina, Division of Gastroenterology, Ioannina, Greece;(19)Nicolae Testemitanu State University of Medicine and Pharmacy of Moldova, Medical Faculty, Chisinau, Moldova- Republic Of;(20)Mater Dei Hospital- Malta, Division of Gastroenterology, Msida, Malta;(21)Lithuanian University of Health Sciences, Department of Gastroenterology, Kaunas, Lithuania;(22)Amiens University Hospital, Gastroenterology Unit, Amiens, France;(23)American Gastroenterology Center, Department of Gastroenterology, Nicosia, Cyprus;(24)University of Padua, Department of Surgical- Oncological and Gastroenterological Sciences, Padova, Italy;(25)Xerencia Xestion Integrada de Vigo- SERGAS, Department of Gastroenterology, Vigo, Spain;(26)SERGAS-UVIGO- Vigo- Spain, Research Group in Digestive Diseases, Galicia Sur Health Research Institute IIS Galicia Sur SERGAS-UVIGO, Spain;(27)Ribera-POVISA Hospital, Department of Gastroenterology, Vigo, Spain;(28)University Hospital Copenhagen – Herlev Hospital, Department of Gastroenterology, Herlev, Denmark;(29)University Hospital Copenhagen – North Zealand Hospital, Department of Gastroenterology, Hillerød, Denmark;Epi-IBD group